Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/CLXyG3NUcu
TARDIS was shown to have up to 100-fold increase in ctDNA detection limits in breast cancer compared to other commonly used methods. $EXAS https://t.co/sSdTcKcok9
'Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer' Read how Streck Cell-Free DNA #blood collection tubes can be used to help guide the treatment and management of #breastcancer patients: http
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer ... https://t.co/MgiuEog7ri
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. https://t.co/dEOOwzM7zY https://t.co/X11zq1Zf8Z
リキッドバイオプシーのためにはバイオプシーが必要、という研究が増加しつつある。皆限界を認識しつつあるようだ。 https://t.co/Z6Ix7giWaX https://t.co/SK0yKfP7Ip #リキッドバイオプシー #がん #癌
the TARDIS paper from a few months ago can be found here: https://t.co/UpZAtBTEQ8
RT @BRMcDonald28: Very excited about our new paper on residual disease detection in early stage cancer using circulating tumor DNA. Lots o…
Interesting paper by McDonald et al. about the use of ctDNA analysis to detect residual disease in breast cancer patients. https://t.co/dyKtiER9bz
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
Fund the Fight. 🏹 Find a Cure. https://t.co/1FEvUJ7MSj
Interesting article from @digitaljournal discussing personalised ctDNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Link to corresponding paper: https://t.co/nFru13y0Wo Link to article: https://t.co/yNs5Xk8NZh
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Science Translational Medicine https://t.co/bEg4h1lPcc
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/DXYbT61ofd
RT @MaryMaryregan: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https:…
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/DXYbT61ofd
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/DXYbT61ofd
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @leowanglab: TARDIS is out! Great work from @TGen’s #murtaza lab collaboration with #slavin and #weitzel @cityofhope. https://t.co/WmHsF…
A new genetics technique, obviously named TARDIS. Early tumor detection, no time travel needed. 😎. https://t.co/ywO24kUTew
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
血中循環腫瘍DNA検出リキッドバイオプシー (3題) https://t.co/fQgYcIpKUi
"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer" McDonald BR [..] Pockaj BA, Murtaza M. Sci Transl Med. 2019-08-07. (bioRixv 2018-09-26). https://t.co/Ofrg0vJRjO TARgeted DIgital Sequencin
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
Novel digital sequencing approaches are driving down the sensitivity of ctDNA analysis whilst maintaining specificity, generating potential clinical utility for personalised ctDNA monitoring in guiding (neo)adjuvant treatment decisions. https://t.co/yr5diQ
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
Testing a personalized circulating tumor DNA assay in early stage breast cancer patients during neoadjuvant therapy achieved up to 100-fold improvement beyond the current limit of ctDNA. https://t.co/K8C4aHSXdf #ctDNA #breastcancer @MayoClinic @TGen @CR
RT @MaryMaryregan: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Scie…
RT @Dr_R_Kurzrock: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Scie…
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/taY4MEMN2U
RT @Dr_R_Kurzrock: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Scie…
RT @MaryMaryregan: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Scie…
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Science Translational Medicine https://t.co/bEg4h1lPcc
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @Dr_R_Kurzrock: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Scie…
@isliquidbiopsy
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Science Translational Medicine https://t.co/rSFVysIZiz
RT @michaelwangmd: This study published in Science Translational Medicine found that personalized ctDNA tracking can enable individualized…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @ESonjar: Para tenerlo en cuenta @aec_mama @aecirujanos @RNCsantander https://t.co/l92xmMq40f
This study published in Science Translational Medicine found that personalized ctDNA tracking can enable individualized clinical management of patients with cancer treated with curative intent. https://t.co/aRuZqXZkgU
RT @ScienceTM: Scientists have created a patient-specific sequencing platform that can sniff out #ctDNA and signs of residual disease after…
RT @scipak_es: Un ensayo personalizado supera los límites para detectar ADN tumoral en pacientes con cáncer de mama @Cambridge_Uni @TGen ht…
RT @okelidokeli: Very interesting paper using personalised ctDNA assays/dynamics to predict neoadjuvant therapy response in localised breas…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
Very interesting paper using personalised ctDNA assays/dynamics to predict neoadjuvant therapy response in localised breast cancer.
RT @cityofhope: @TGen The study was published in Science Translational Medicine and done in collaboration with researchers from City of Hop…
RT @ESonjar: Para tenerlo en cuenta @aec_mama @aecirujanos @RNCsantander https://t.co/l92xmMq40f
RT @ESonjar: Para tenerlo en cuenta @aec_mama @aecirujanos @RNCsantander https://t.co/l92xmMq40f
RT @ESonjar: Para tenerlo en cuenta @aec_mama @aecirujanos @RNCsantander https://t.co/l92xmMq40f
RT @ESonjar: Para tenerlo en cuenta @aec_mama @aecirujanos @RNCsantander https://t.co/l92xmMq40f
Para tenerlo en cuenta @aec_mama @aecirujanos @RNCsantander
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer | Science Translational Medicine https://t.co/1VroJn1tCW
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @NicoleKuderer: #WeeklyMusings #42 Personalized #cancer monitoring with liquid biopsies has arrived for early stage pts! Looking forward…
RT @UroDocAsh: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.…
RT @NicoleKuderer: #WeeklyMusings #42 Personalized #cancer monitoring with liquid biopsies has arrived for early stage pts! Looking forward…
RT @LeeWilke: Incredible step forward in personalized detection of residual disease with a surgeon as a lead author! Barb Pockaj from Mayo…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @NicoleKuderer: #WeeklyMusings #42 Personalized #cancer monitoring with liquid biopsies has arrived for early stage pts! Looking forward…
RT @UroDocAsh: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.…
RT @NicoleKuderer: #WeeklyMusings #42 Personalized #cancer monitoring with liquid biopsies has arrived for early stage pts! Looking forward…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in #breastcancer publ. in @sciencemagazine https://t.co/h7eV1GIE81
Incredible step forward in personalized detection of residual disease with a surgeon as a lead author! Barb Pockaj from Mayo Scottsdale Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https:
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
Scientists have created a patient-specific sequencing platform that can sniff out #ctDNA and signs of residual disease after treatment in women with #breastcancer. @TGen #PersonalizedMedicine https://t.co/UeGUIcqhwO https://t.co/3IVB4UwUvP
RT @NicoleKuderer: #WeeklyMusings #42 Personalized #cancer monitoring with liquid biopsies has arrived for early stage pts! Looking forward…
#WeeklyMusings #42 Personalized #cancer monitoring with liquid biopsies has arrived for early stage pts! Looking forward to validations in ongoing trials to find true pCR & clinical CR. Could some of the pts with residual ctDNA despite pCR be CHIP or a
Awesome to see this work published and featured in many news articles! The hype is real, can't wait to see what's next for TARDIS
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
RT @mehreenkisat: What would Halsted say! @TGen @MayoClinic @CRUK_CI @cityofhope @ZainHashmiMD @NabeelZafarMD @MustafaRaoofMD https://t.co/…
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @prat_aleix: aunque existen ya tests comerciales para detectar ctDNA en este contexto, pido cautela. No deberían usarse sin tener claro…
RT @ctSEQ_papers: PubMed_ Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer…
RT @mehreenkisat: What would Halsted say! @TGen @MayoClinic @CRUK_CI @cityofhope @ZainHashmiMD @NabeelZafarMD @MustafaRaoofMD https://t.co/…
PubMed_ Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. https://t.co/qq33UPOWMM
RT @mehreenkisat: What would Halsted say! @TGen @MayoClinic @CRUK_CI @cityofhope @ZainHashmiMD @NabeelZafarMD @MustafaRaoofMD https://t.co/…
RT @mehreenkisat: What would Halsted say! @TGen @MayoClinic @CRUK_CI @cityofhope @ZainHashmiMD @NabeelZafarMD @MustafaRaoofMD https://t.co/…
What would Halsted say! @TGen @MayoClinic @CRUK_CI @cityofhope @ZainHashmiMD @NabeelZafarMD @MustafaRaoofMD
RT @UroDocAsh: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.…